
About mk2 Biotechnologies
mk2 Biotechnologies is a Healthcare company based in Munchen (Germany) founded in 2017 by Marco Giuman and Sebastian Mangold. Peptides and proteins are developed for life science applications. Its chief executive, as recorded, is Konstantinos Antonopoulos. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Proteomics. Its legal entity is mk2 Biotechnologies GmbH.
Company details
mk2 Biotechnologies was founded in 2017 in Munich, Germany, within the biotechnology sector. A scalable technology for peptide and protein synthesis is utilized, relying on recombinant methods to support production across various chain lengths. Services are provided to clients in research, development, agriculture, and stock breeding, facilitating applications in these fields. Operations focus on enabling large-scale manufacturing for life science needs.
- InvestorsSeedBlink
& 2 more
Funding Insights of mk2 Biotechnologies
- Total Rounds 1
- Investors Count 3
All 1 funding rounds of mk2 Biotechnologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | Seed | β | OCCIDENT – The Science Investor. |
3 investors in total: 3 institutional.
Investors in mk2 Biotechnologies
mk2 Biotechnologies has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include SeedBlink, Gateway Ventures and OCCIDENT.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are provided to deep-tech startups. | occident.group | Munich, Germany | ||
An online platform is operated for crowdfunding investments in startups. | 2015 | gateway.ventures | Vienna, Austria | |
Investments in pre-seed and seed-stage startups are facilitated for individuals. | 2019 | seedblink.com | Bucharest, Romania |
Investor details for mk2 Biotechnologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of mk2 Biotechnologies
7 people are tracked at mk2 Biotechnologies (5 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Marco Giuman | Co-Founder & CTO | Leadership |
Sebastian Mangold | Co-Founder & Managing Director | Leadership |
Konstantinos Antonopoulos | CEO | Leadership |
Kritan Gautam | Head Of Research & Development | Leadership |
Patrick Wiesbeck | Head Of Science & Innovation | Leadership |
Oliver Piech | Science & Innovation Manager | Team |
Viola Kallfaß | Development Specialist | Team |
Complete people profiles for mk2 Biotechnologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of mk2 Biotechnologies
2 dated milestones of mk2 Biotechnologies across 4 years, from founding to its latest funding, stage changes and deals.
- Founded mk2 Biotechnologies is founded.
- Funding First funding round.
Web traffic of mk2 Biotechnologies
Websites that share an audience with mk2 Biotechnologies (mk2.bio).
Websites whose visitors overlap most with mk2 Biotechnologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| leukocare.com | 100% | 5.7K | #3,715,251 | View details | |
| project-pharmaceutics.com | 100% | View details | |||
amicusrx.de | amicusrx.de | 99% | #10,724,948 | β | |
| viramed.de | 99% | View details | |||
| scirhom.com | 98% | View details | |||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 19 similar websites and full traffic analytics for mk2 Biotechnologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about mk2 Biotechnologies
mk2 Biotechnologies was founded in 2017 and raised its 1st funding round 4 years after it was founded.
mk2 Biotechnologies is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Konstantinos Antonopoulos is the CEO of mk2 Biotechnologies, as recorded in our data.
mk2 Biotechnologies was founded in 2017 in Munich, Germany, within the biotechnology sector. A scalable technology for peptide and protein synthesis is utilized, relying on recombinant methods to support production across various chain lengths. Services are provided to clients in research, development, agriculture, and stock breeding, facilitating applications in these fields. Operations focus on enabling large-scale manufacturing for life science needs.
mk2 Biotechnologies has 3 investors. Key investors include SeedBlink, Gateway Ventures, and OCCIDENT.
mk2 Biotechnologies operates through Mk2 Biotechnologies Gmbh.